Faculty

Siddhartha Yadav, M.B.B.S., M.D.

Clinical Studies

MC1733, Phase I Trial of intratumoral administration of a measles virus derivative expressing the Helicobacter pylori neutrophil-activating protein (NAP) (MV-s-NAP) in patients with metastatic breast cancer Rochester, Minn.
To determine the maximally tolerated dose (MTD) of intratumoral administration of an Edmonston strain measeles virus genetically engineered to express NAP (MV-s-NAP) in patients with metastatic breast cancer; to determine the safety and toxicity of on-time and serial administration of MV-s-NAP in patients with metastic breast cancer.

A Study on the Feasibility of Investigating Associations between Environmental Exposures and Breast Cancer Risk among School Employees Rochester, Minn.
The purpose of this study is to conduct exploratory comparisons of 1) the environmental exposures of the cases and controls through numerous methodologies including metal analysis, metabolomics, and exposomics. Samples collected will include hair, nails, blood, and urine.
Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients With Molecularly Selected Cancers (ATTACC) (ATTACC) Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The primary purpose of this study is to assess the safety and tolerability of Niraparib or Olaparib in combination with RP-3500, in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-3500 in combination with Niraparib or Olaparib, examine pharmacokinetics (PK) and assess anti-tumor activity.